AbbVie’s Allergan Sues Sun, MSN Labs Over New Viberzi Patent

AbbVie Inc. renewed its courtroom effort to block copies of Viberzi, separately suing two companies whose generic versions it said infringe a patent issued last month for abuse-deterrent formulations of the treatment for irritable bowel syndrome with diarrhea.

AbbVie and three subsidiaries—Allergan Holdings Unlimited Co., AbbVie US LLC, and Eden Biodesign LLC—allege that Viberzi copies proposed by Sun Pharmaceutical Industries Ltd. and MSN Laboratories Private Ltd. infringe US Patent No. 12,097,187, according to complaints filed Wednesday in the US District Court for the District of Delaware. Neither MSN nor Sun immediately responded to requests for comments.

The patent—which covers ...